CTXR News & Events

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, (CTXR), announced the initial shipment of LYMPHIR to Europe through one of its regional distribution partners, marking an important milestone in expanding access to the therapy for patients outside the United States. LYMPHIR will be made available to eligible patients through Named Patient Programs, or NPPs, in accordance with local regulations in each country. The initiation of European distribution represents a strategic step in the Company's broader effort to extend access to LYMPHIR for patients with limited treatment options, while continuing to prioritize disciplined and targeted market entry. LYMPHIR was approved by the U.S. Food and Drug Administration in August 2024 for the treatment of adult patients with Stage I-III relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, and was commercially launched in the United States in December 2025. LYMPHIR does not have marketing authorization from the European Medicines Agency in Europe or other countries outside the U.S. Access is being provided solely through Named Patient Programs in accordance with applicable local laws and regulations.

Citius Pharmaceuticals announced that it has entered into a definitive agreement for the purchase of an aggregate of 5,076,143 shares of its common stock at a purchase price of 98.5c per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 5,076,143 shares of common stock at an exercise price of 86c per share that will be exercisable immediately upon issuance and will expire five years following the effective date of a registration statement registering the shares issuable upon exercise of the warrants. The closing of the offering is expected to occur on or about April 24, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the company from the offering are expected to be approximately $5M, before deducting the placement agent fees and other offering expenses payable by the company. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Citius Pharmaceuticals has received $3.8M in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss Program, funded through the New Jersey Economic Development Authority, or NJEDA.

Revenue of $3.9M during the quarter ended December 31, 2025 reflects sales related to the launch of Lymphir. Cash and cash equivalents totaled $7.3M as of December 31, 2025 .